ATENZA XR (Arrotex Pharmaceuticals Pty Ltd)

[TRADENAME] is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Treatment should be commenced by a specialist.

A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years.

Need for comprehensive treatment programme

[TRADENAME] is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational and social) for patients with this syndrome. Stimulants are not intended for use in the patient who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms.

Long term use

The effectiveness of [TRADENAME] for long-term use has not been systematically evaluated in controlled trials. Therefore the physician who elects to use [TRADENAME] for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.